287 related articles for article (PubMed ID: 28335764)
1. Health care cost associated with the use of enzyme-inducing and non-enzyme-active antiepileptic drugs in the UK: a long-term retrospective matched cohort study.
Borghs S; Thieffry S; Noack-Rink M; Dedeken P; Hong LS; Byram L; Logan J; Chan J; Kiri V
BMC Neurol; 2017 Mar; 17(1):59. PubMed ID: 28335764
[TBL] [Abstract][Full Text] [Related]
2. Comparing healthcare cost associated with the use of enzyme-inducing and non-enzyme active antiepileptic drugs in elderly patients with epilepsy in the UK: a long-term retrospective, matched cohort study.
Borghs S; Byram L; Chan J; Dedeken P; Logan J; Kiri V; Noack-Rink M; Patsalos PN; Thieffry S
BMC Neurol; 2020 Jan; 20(1):7. PubMed ID: 31914953
[TBL] [Abstract][Full Text] [Related]
3. Cost-benefit analysis, cost-effectiveness analysis, and impact of antiepileptic drugs on the risk of fracture in patients with epilepsy: A nationwide cohort study.
Cheng HH; Kung PT; Wang BR; Chiu LT; Tsai WC
Epilepsy Behav; 2020 Feb; 103(Pt A):106851. PubMed ID: 31889639
[TBL] [Abstract][Full Text] [Related]
4. Use of antiepileptic drugs and lipid-lowering agents in the United States.
Mintzer S; Maio V; Foley K
Epilepsy Behav; 2014 May; 34():105-8. PubMed ID: 24735835
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burden of breakthrough seizures.
Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
[TBL] [Abstract][Full Text] [Related]
6. Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use.
Cramer JA; Wang ZJ; Chang E; Copher R; Cherepanov D; Broder MS
Epilepsy Behav; 2015 Mar; 44():40-6. PubMed ID: 25635369
[TBL] [Abstract][Full Text] [Related]
7. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.
Strzelczyk A; Haag A; Reese JP; Nickolay T; Oertel WH; Dodel R; Knake S; Rosenow F; Hamer HM
Epilepsy Behav; 2013 Jun; 27(3):433-8. PubMed ID: 23591262
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
Davis KL; Candrilli SD; Edin HM
Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
[TBL] [Abstract][Full Text] [Related]
9. Antiepileptic Drug Titration and Related Health Care Resource Use and Costs.
Fishman J; Kalilani L; Song Y; Swallow E; Wild I
J Manag Care Spec Pharm; 2018 Sep; 24(9):929-938. PubMed ID: 29486142
[TBL] [Abstract][Full Text] [Related]
10. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview.
Willems LM; Richter S; Watermann N; Bauer S; Klein KM; Reese JP; Schöffski O; Hamer HM; Knake S; Rosenow F; Strzelczyk A
Epilepsy Behav; 2018 Jun; 83():28-35. PubMed ID: 29649671
[TBL] [Abstract][Full Text] [Related]
11. Lacosamide and concomitant use of antiepileptic and other medications in a US population - A retrospective cohort study.
Kalilani L; Lu C; Pierre-Louis B; Gold M
Epilepsy Behav; 2017 Jul; 72():51-57. PubMed ID: 28575767
[TBL] [Abstract][Full Text] [Related]
12. Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany.
Strzelczyk A; Bergmann A; Biermann V; Braune S; Dieterle L; Forth B; Kortland LM; Lang M; Peckmann T; Schöffski O; Sigel KO; Rosenow F
Epilepsy Behav; 2016 Nov; 64(Pt A):75-82. PubMed ID: 27732920
[TBL] [Abstract][Full Text] [Related]
13. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
14. Impact of enzyme-inducing anti-epilepsy drugs on lipid levels in elderly patients with epilepsy.
Okada S; Nishina M; Koizumi K; Katayama M; Inoue S; Suga S
Epilepsy Res; 2020 Oct; 166():106428. PubMed ID: 32702537
[TBL] [Abstract][Full Text] [Related]
15. Economic burden associated with the use of generic antiepileptic drugs in the United States.
Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
[TBL] [Abstract][Full Text] [Related]
16. Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy: a retrospective cohort study in the UK Clinical Practice Research Datalink (CPRD).
Shepherd C; Koepp M; Myland M; Patel K; Miglio C; Siva V; Gray E; Neary M
BMJ Open; 2017 Oct; 7(10):e015236. PubMed ID: 28982809
[TBL] [Abstract][Full Text] [Related]
17. Enzyme-inducing antiepileptic drugs and fractures in people with epilepsy: A systematic review.
Fraser LA; Burneo JG; Fraser JA
Epilepsy Res; 2015 Oct; 116():59-66. PubMed ID: 26354168
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
Markowitz MA; Mauskopf JA; Halpern MT
Neurology; 1998 Oct; 51(4):1026-33. PubMed ID: 9781524
[TBL] [Abstract][Full Text] [Related]
19. Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the General Practice Research Database.
Nicholas JM; Ridsdale L; Richardson MP; Ashworth M; Gulliford MC
Seizure; 2012 Jul; 21(6):466-70. PubMed ID: 22608976
[TBL] [Abstract][Full Text] [Related]
20. Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study.
Renoux C; Dell'Aniello S; Saarela O; Filion KB; Boivin JF
BMJ Open; 2015 Aug; 5(8):e008365. PubMed ID: 26270948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
